141 related articles for article (PubMed ID: 35646981)
1. A Network Pharmacology Study: Reveal the Mechanisms of Palovarotene Against Heterotopic Ossification.
Huang J; Liu D; Zhang J; Xiao H
Front Med (Lausanne); 2022; 9():897392. PubMed ID: 35646981
[TBL] [Abstract][Full Text] [Related]
2. Palovarotene inhibits the NF-κB signalling pathway to prevent heterotopic ossification.
Huang J; Wu J; Lin J; Li C; Tang B; Xiao H
Clin Exp Pharmacol Physiol; 2022 Aug; 49(8):881-892. PubMed ID: 35638441
[TBL] [Abstract][Full Text] [Related]
3. Palovarotene Can Attenuate Heterotopic Ossification Induced by Tendon Stem Cells by Downregulating the Synergistic Effects of Smad and NF-
Huang J; Lin J; Li C; Tang B; Xiao H
Stem Cells Int; 2022; 2022():1560943. PubMed ID: 35530413
[TBL] [Abstract][Full Text] [Related]
4. Targeted stimulation of retinoic acid receptor-γ mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model.
Pavey GJ; Qureshi AT; Tomasino AM; Honnold CL; Bishop DK; Agarwal S; Loder S; Levi B; Pacifici M; Iwamoto M; Potter BK; Davis TA; Forsberg JA
Bone; 2016 Sep; 90():159-67. PubMed ID: 27368930
[TBL] [Abstract][Full Text] [Related]
5. Palovarotene Action Against Heterotopic Ossification Includes a Reduction of Local Participating Activin A-Expressing Cell Populations.
Mundy C; Yao L; Shaughnessy KA; Saunders C; Shore EM; Koyama E; Pacifici M
JBMR Plus; 2023 Dec; 7(12):e10821. PubMed ID: 38130748
[TBL] [Abstract][Full Text] [Related]
6. Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report.
Singh S; Kidane J; Wentworth KL; Motamedi D; Morshed S; Schober AE; Hsiao EC
BMC Musculoskelet Disord; 2020 Apr; 21(1):204. PubMed ID: 32245464
[TBL] [Abstract][Full Text] [Related]
7. Palovarotene inhibits connective tissue progenitor cell proliferation in a rat model of combat-related heterotopic ossification.
Wheatley BM; Cilwa KE; Dey D; Qureshi AT; Seavey JG; Tomasino AM; Sanders EM; Bova W; Boehm CA; Iwamoto M; Potter BK; Forsberg JA; Muschler GF; Davis TA
J Orthop Res; 2018 Apr; 36(4):1135-1144. PubMed ID: 28960501
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent.
Sinha S; Uchibe K; Usami Y; Pacifici M; Iwamoto M
Bone; 2016 Sep; 90():59-68. PubMed ID: 26891836
[TBL] [Abstract][Full Text] [Related]
9. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
[TBL] [Abstract][Full Text] [Related]
10. Erianin, the main active ingredient of Dendrobium chrysotoxum Lindl, inhibits precancerous lesions of gastric cancer (PLGC) through suppression of the HRAS-PI3K-AKT signaling pathway as revealed by network pharmacology and in vitro experimental verification.
Wang Y; Chu F; Lin J; Li Y; Johnson N; Zhang J; Gai C; Su Z; Cheng H; Wang L; Ding X
J Ethnopharmacol; 2021 Oct; 279():114399. PubMed ID: 34246740
[TBL] [Abstract][Full Text] [Related]
11. Palovarotene: First Approval.
Hoy SM
Drugs; 2022 Apr; 82(6):711-716. PubMed ID: 35384641
[TBL] [Abstract][Full Text] [Related]
12. Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity.
Lees-Shepard JB; Nicholas SE; Stoessel SJ; Devarakonda PM; Schneider MJ; Yamamoto M; Goldhamer DJ
Elife; 2018 Sep; 7():. PubMed ID: 30226468
[TBL] [Abstract][Full Text] [Related]
13. [Mechanism of Carthami Flos and Lepidii Semen drug pair in inhibition of myocardial fibrosis by improving cardiac microenvironment based on network pharmacology and animal experiment].
Wang Y; Wang Z; Wang C; Ma DF
Zhongguo Zhong Yao Za Zhi; 2022 Feb; 47(3):753-763. PubMed ID: 35178959
[TBL] [Abstract][Full Text] [Related]
14. Integrating Network Pharmacology and Experimental Verification to Explore the Pharmacological Mechanisms of Aloin Against Gastric Cancer.
Gao J; Yang S; Xie G; Pan J; Zhu F
Drug Des Devel Ther; 2022; 16():1947-1961. PubMed ID: 35757520
[TBL] [Abstract][Full Text] [Related]
15. Identification of the Biomarkers and Pathological Process of Heterotopic Ossification: Weighted Gene Co-Expression Network Analysis.
Wang S; Tian J; Wang J; Liu S; Ke L; Shang C; Yang J; Wang L
Front Endocrinol (Lausanne); 2020; 11():581768. PubMed ID: 33391181
[TBL] [Abstract][Full Text] [Related]
16. [Mechanism of astragaloside Ⅳ alleviating PC12 cell injury by activating PI3K/AKT signaling pathway: based on network pharmacology and in vitro experiments].
Zhang TQ; Li CC; Zhang TF; Wang MY; Cui SN; Huo Q
Zhongguo Zhong Yao Za Zhi; 2021 Dec; 46(24):6465-6473. PubMed ID: 34994139
[TBL] [Abstract][Full Text] [Related]
17. Uncovering the pharmacological mechanism of Wei-Tong-Xin against gastric ulcer based on network pharmacology combined with in vivo experiment validation.
Liu W; Zhang X; Ma T; Wang J; Lv X; Wu B; Yan T; Jia Y
J Ethnopharmacol; 2022 Jul; 293():115282. PubMed ID: 35405254
[TBL] [Abstract][Full Text] [Related]
18. [Effect and mechanism of Jingqi Yukui Capsules on gastric ulcer mucosa healing quality: based on network pharmacology and animal experiment].
Fan MJ; Duan YQ; Li NL; Yang XY; Ma J; Gong ZH; Wang DK
Zhongguo Zhong Yao Za Zhi; 2022 Mar; 47(5):1350-1358. PubMed ID: 35343164
[TBL] [Abstract][Full Text] [Related]
19. Potential genes and pathways associated with heterotopic ossification derived from analyses of gene expression profiles.
Yang Z; Liu D; Guan R; Li X; Wang Y; Sheng B
J Orthop Surg Res; 2021 Aug; 16(1):499. PubMed ID: 34389038
[TBL] [Abstract][Full Text] [Related]
20. Exploration of the Effect and Potential Mechanism of Echinacoside Against Endometrial Cancer Based on Network Pharmacology and in vitro Experimental Verification.
Shu W; Wang Z; Zhao R; Shi R; Zhang J; Zhang W; Wang H
Drug Des Devel Ther; 2022; 16():1847-1863. PubMed ID: 35734366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
